These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 18625763

  • 1. Lack of a significant drug interaction between raltegravir and tenofovir.
    Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M.
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
    [Abstract] [Full Text] [Related]

  • 2. Raltegravir as effective as efavirenz in 144-week data.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
    [No Abstract] [Full Text] [Related]

  • 3. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M.
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [Abstract] [Full Text] [Related]

  • 4. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [Abstract] [Full Text] [Related]

  • 5. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
    Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Breidinger SA, Mangin EC, Azrolan N, Greenberg HE, Haazen W, Stone JA, Gottesdiener KM, Wagner JA.
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
    [Abstract] [Full Text] [Related]

  • 6. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A.
    Antivir Ther; 2010 Dec; 15(2):213-8. PubMed ID: 20386076
    [Abstract] [Full Text] [Related]

  • 7. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
    Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P, STARTMRK Investigators.
    J Acquir Immune Defic Syndr; 2013 May 01; 63(1):77-85. PubMed ID: 23412015
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
    Piscitelli S, Kim J, Gould E, Lou Y, White S, de Serres M, Johnson M, Zhou XJ, Pietropaolo K, Mayers D.
    Br J Clin Pharmacol; 2012 Aug 01; 74(2):336-45. PubMed ID: 22288567
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
    Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H, Protocol 004 Part II Study Team.
    J Acquir Immune Defic Syndr; 2007 Oct 01; 46(2):125-33. PubMed ID: 17721395
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W, Sudjaritruk T, Chokephaibulkit K.
    Pediatr Infect Dis J; 2015 Apr 01; 34(4):392-7. PubMed ID: 25760566
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M, Langdon G, Labadie RR, Layton G, Ndongo MN, Banerjee S, Davis J.
    Antimicrob Agents Chemother; 2012 Feb 01; 56(2):887-92. PubMed ID: 22123705
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
    German P, Warren D, West S, Hui J, Kearney BP.
    J Acquir Immune Defic Syndr; 2010 Nov 01; 55(3):323-9. PubMed ID: 20683270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.